[{"NetIncomeLoss_1_Q2_USD":-77456000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"DepreciationAndAmortization_1_Q2_USD":2100000.0,"DepreciationAndAmortization_2_Q2_USD":4002000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":33430000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":16392000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":64592000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":67975000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":-93000.0,"RestrictedCashCurrent_0_Q2_USD":194000.0,"InterestPaidNet_2_Q2_USD":37000.0,"PaymentsToAcquireShortTermInvestments_2_Q2_USD":228224000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":810000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-91398000.0,"AssetsCurrent_0_Q2_USD":358987000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":11917445.0,"IncomeTaxesPaidNet_2_Q2_USD":1000.0,"CommonStockSharesIssued_0_Q2_shares":74308000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":346501000.0,"Assets_0_Q2_USD":428111000.0,"ShareBasedCompensation_2_Q2_USD":26592000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":606000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":590000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_2_Q2_USD":541000.0,"Liabilities_0_Q2_USD":46986000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":61560000.0,"ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_2_Q2_USD":140235000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":197000.0,"ProceedsFromStockPlans_2_Q2_USD":3234000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":1685000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":497000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":1000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":1000.0,"InvestmentIncomeNetAmortizationOfDiscountAndPremium_2_Q2_USD":-170000.0,"CommonStockValue_0_Q2_USD":7000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":13321000.0,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0_Q2_USD":38009000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0_Q2_USD":308021000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":215272000.0,"RestrictedCash_0_Q2_USD":1400000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-150375000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-76850000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-2933000.0,"OtherAssetsNoncurrent_0_Q2_USD":1016000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":74511000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":13420000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1349234000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_2_Q2_USD":-2049000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":119219000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":16335544.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":24172000.0,"CommonStockSharesOutstanding_0_Q2_shares":74308000.0,"RestrictedCashNoncurrent_0_Q2_USD":1200000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":15504000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-150964000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-77455000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_2_Q2_USD":0.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":1395000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":13948000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-123680000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q2_USD":308492000.0,"LiabilitiesCurrent_0_Q2_USD":31684000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":194000.0,"AccountsPayableCurrent_0_Q2_USD":5106000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":75905000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":11081000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":288000.0,"InterestReceivable_0_Q2_USD":800000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":253000.0,"ProceedsFromPaymentsForOtherFinancingActivities_2_Q2_USD":-165000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":53587000.0,"NetIncomeLoss_2_Q2_USD":-150965000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-968926000.0,"AccretionExpense_2_Q2_USD":38000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":3409000.0,"StockholdersEquity_0_Q2_USD":381125000.0,"IncreaseDecreaseInOtherCurrentLiabilities_2_Q2_USD":-406000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0_Q2_USD":37670000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-1423000.0,"CommonStockSharesAuthorized_0_Q2_shares":500000000.0,"OperatingIncomeLoss_2_Q2_USD":-152649000.0,"OperatingIncomeLoss_1_Q2_USD":-77952000.0,"AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_0_Q2_USD":345691000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":428111000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":12657000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"PreferredStockSharesAuthorized_0_Q2_shares":20000000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":13948000.0,"CapitalUnitsAuthorized_0_Q2_shares":520000000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":69091000.0,"OperatingExpenses_2_Q2_USD":152649000.0,"OperatingExpenses_1_Q2_USD":77952000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.34,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.14,"ProfitLoss_2_Q2_USD":-150965000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":1882000.0,"OtherLiabilitiesCurrent_0_Q2_USD":5677000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":26592000.0,"ShortTermInvestments_0_Q2_USD":273201000.0,"Ticker":"ATRA","CIK":"1604464","name":"ATARA BIOTHERAPEUTICS, INC.","OfficialName":"Atara Biotherapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"734540687.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200805"}]